This podcast episode explores the potential economic impact and societal implications of weight-loss drugs, particularly the GLP-1 class of drugs such as Azempic and Wagovi. The speakers discuss the current market size and growth potential for obesity drugs, the ongoing shortages and supply constraints of these drugs, and the significant economic costs of obesity. They also speculate on how widely available and affordable weight-loss drugs could reshape societal norms and beauty standards. Overall, the episode highlights the hope for these drugs to address the economic burden of obesity while raising concerns about their accessibility and long-term market dynamics.